Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Aug;41(8):1704–1708. doi: 10.1128/aac.41.8.1704

Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients.

D Yamamura 1, R Gucalp 1, P Carlisle 1, M Cimino 1, J Roberts 1, C Rotstein 1
PMCID: PMC163989  PMID: 9257745

Abstract

An open-label randomized trial comparing the efficacy and safety of cefepime versus piperacillin plus gentamicin (P+G) given intravenously for the treatment of febrile episodes in neutropenic patients with underlying malignancy was conducted at two oncology centers. Over a 30-month period 111 patients were enrolled and 99 patients were found to be suitable for evaluation. At the 72-h time of evaluation, cefepime monotherapy and P+G combination therapy produced comparable clinical response rates (78% for both). P+G and cefepime produced comparable response rates in microbiologically documented (78 versus 71%), clinically documented (100 versus 100%), and possible (75 versus 79%) infections. The P+G and cefepime treatments achieved comparable microbiological eradication of gram-negative (100 versus 71%) (P = 0.09) and gram-positive (44 versus 70%) (P = 0.37) organisms. There were no statistically significant differences in the rates of superinfection between the groups; however, more superinfections of fungal origin were noted in the P+G group. Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy. Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients.

Full Text

The Full Text of this article is available as a PDF (181.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodey G. P. Antibiotics in patients with neutropenia. Arch Intern Med. 1984 Sep;144(9):1845–1851. [PubMed] [Google Scholar]
  2. De Pauw B. E., Deresinski S. C., Feld R., Lane-Allman E. F., Donnelly J. P. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group. Ann Intern Med. 1994 May 15;120(10):834–844. doi: 10.7326/0003-4819-120-10-199405150-00004. [DOI] [PubMed] [Google Scholar]
  3. Eggimann P., Glauser M. P., Aoun M., Meunier F., Calandra T. Cefepime monotherapy for the empirical treatment of fever in granulocytopenic cancer patients. J Antimicrob Chemother. 1993 Nov;32 (Suppl B):151–163. doi: 10.1093/jac/32.suppl_b.151. [DOI] [PubMed] [Google Scholar]
  4. Fuchs P. C., Jones R. N., Barry A. L., Thornsberry C. Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin. J Clin Microbiol. 1986 Mar;23(3):634–636. doi: 10.1128/jcm.23.3.634-636.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gentry L. O., Rodriguez-Gomez G. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Antimicrob Agents Chemother. 1991 Nov;35(11):2371–2374. doi: 10.1128/aac.35.11.2371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Giuliano M., Barza M., Jacobus N. V., Gorbach S. L. Effect of broad-spectrum parenteral antibiotics on composition of intestinal microflora of humans. Antimicrob Agents Chemother. 1987 Feb;31(2):202–206. doi: 10.1128/aac.31.2.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hardin T. C., Jennings T. S. Cefepime. Pharmacotherapy. 1994 Nov-Dec;14(6):657–668. [PubMed] [Google Scholar]
  8. Hughes W. T., Armstrong D., Bodey G. P., Feld R., Mandell G. L., Meyers J. D., Pizzo P. A., Schimpff S. C., Shenep J. L., Wade J. C. From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990 Mar;161(3):381–396. doi: 10.1093/infdis/161.3.381. [DOI] [PubMed] [Google Scholar]
  9. Huijgens P. C., Ossenkoppele G. J., Weijers T. F., van Loenen A. C., Simoons-Smit A. M., Wijermans P. W., van Pampus E. C., Langenhuijsen M. M. Imipenem-cilastatin for empirical therapy in neutropenic patients with fever: an open study in patients with hematologic malignancies. Eur J Haematol. 1991 Jan;46(1):42–46. doi: 10.1111/j.1600-0609.1991.tb00512.x. [DOI] [PubMed] [Google Scholar]
  10. Kieft H., Hoepelman A. I., Rozenberg-Arska M., Branger J. M., Voskuil J. H., Geers A. B., Kluyver M., Hart H. C., Poest-Clement E., van Beugen L. Cefepime compared with ceftazidime as initial therapy for serious bacterial infections and sepsis syndrome. Antimicrob Agents Chemother. 1994 Mar;38(3):415–421. doi: 10.1128/aac.38.3.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Malik I. A., Abbas Z., Karim M. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients. Lancet. 1992 May 2;339(8801):1092–1096. doi: 10.1016/0140-6736(92)90674-r. [DOI] [PubMed] [Google Scholar]
  12. Neu H. C., Chin N. X., Jules K., Labthavikul P. The activity of BMY 28142 a new broad spectrum beta-lactamase stable cephalosporin. J Antimicrob Chemother. 1986 Apr;17(4):441–452. doi: 10.1093/jac/17.4.441. [DOI] [PubMed] [Google Scholar]
  13. Nikaido H., Liu W., Rosenberg E. Y. Outer membrane permeability and beta-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother. 1990 Feb;34(2):337–342. doi: 10.1128/aac.34.2.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pizzo P. A., Hathorn J. W., Hiemenz J., Browne M., Commers J., Cotton D., Gress J., Longo D., Marshall D., McKnight J. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med. 1986 Aug 28;315(9):552–558. doi: 10.1056/NEJM198608283150905. [DOI] [PubMed] [Google Scholar]
  15. Pizzo P. A. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993 May 6;328(18):1323–1332. doi: 10.1056/NEJM199305063281808. [DOI] [PubMed] [Google Scholar]
  16. Rolston K. V., Berkey P., Bodey G. P., Anaissie E. J., Khardori N. M., Joshi J. H., Keating M. J., Holmes F. A., Cabanillas F. F., Elting L. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992 Feb;152(2):283–291. [PubMed] [Google Scholar]
  17. Rotstein C., Cimino M., Winkey K., Cesari C., Fenner J. Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients. Am J Med. 1988 Jul 25;85(1A):36–43. doi: 10.1016/0002-9343(88)90173-8. [DOI] [PubMed] [Google Scholar]
  18. Rubin M., Hathorn J. W., Marshall D., Gress J., Steinberg S. M., Pizzo P. A. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med. 1988 Jan;108(1):30–35. doi: 10.7326/0003-4819-108-1-30. [DOI] [PubMed] [Google Scholar]
  19. Rubio M., Palau L., Vivas J. R., del Potro E., Diaz-Mediavilla J., Alvarez A., Martinez R., Picazo J. J. Predominance of gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies. Infect Control Hosp Epidemiol. 1994 Feb;15(2):101–104. doi: 10.1086/646869. [DOI] [PubMed] [Google Scholar]
  20. Sanders C. C. Cefepime: the next generation? Clin Infect Dis. 1993 Sep;17(3):369–379. [PubMed] [Google Scholar]
  21. Sanders C. C., Sanders W. E., Jr Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications. J Infect Dis. 1985 Mar;151(3):399–406. doi: 10.1093/infdis/151.3.399. [DOI] [PubMed] [Google Scholar]
  22. Sanders J. W., Powe N. R., Moore R. D. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis. 1991 Nov;164(5):907–916. doi: 10.1093/infdis/164.5.907. [DOI] [PubMed] [Google Scholar]
  23. Schrank J. H., Jr, Kelly J. W., McAllister C. K. Randomized comparison of cefepime and ceftazidime for treatment of hospitalized patients with gram-negative bacteremia. Clin Infect Dis. 1995 Jan;20(1):56–58. doi: 10.1093/clinids/20.1.56. [DOI] [PubMed] [Google Scholar]
  24. Wade J. C., Schimpff S. C., Newman K. A., Wiernik P. H. Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med. 1982 Oct;97(4):503–508. doi: 10.7326/0003-4819-97-4-503. [DOI] [PubMed] [Google Scholar]
  25. Winston D. J., Dudnick D. V., Chapin M., Ho W. G., Gale R. P., Martin W. J. Coagulase-negative staphylococcal bacteremia in patients receiving immunosuppressive therapy. Arch Intern Med. 1983 Jan;143(1):32–36. [PubMed] [Google Scholar]
  26. Winston D. J., Ho W. G., Bruckner D. A., Champlin R. E. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med. 1991 Dec 1;115(11):849–859. doi: 10.7326/0003-4819-115-11-849. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES